Janice S Kim

4PUBLICATIONS
74CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jul 02, 2026
CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

|Jun 10, 2024
Time Toxicity Experienced by Early-Phase Cancer Clinical Trial Participants.

Sienna M Durbin, Debra M Lundquist, Andrea Pelletier

|Mar 22, 2024
The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life.

Anne Loeser, Janice S Kim, Jeffrey Peppercorn

|Nov 02, 2023
Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.

Andreas Varkaris, Ferran Fece de la Cruz, Elizabeth E Martin

Pageof 1

Frequent Collaborators

4 joint publications

Dejan Juric

3 joint publications

Allison M Kehlmann

2 joint publications

Aditya Bardia

2 joint publications

Ioannis Sanidas